Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 472

1.

British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary.

Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B.

Rheumatology (Oxford). 2020 Jan 23. pii: kez664. doi: 10.1093/rheumatology/kez664. [Epub ahead of print] No abstract available.

PMID:
31970410
2.

British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis.

Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B.

Rheumatology (Oxford). 2020 Jan 23. pii: kez672. doi: 10.1093/rheumatology/kez672. [Epub ahead of print] No abstract available.

PMID:
31970405
3.

Longitudinal relationships between rheumatoid factor and cytokine expression by immunostimulated peripheral blood lymphocytes from patients with rheumatoid arthritis: New insights into B-cell activation.

Davis JM 3rd, Crowson CS, Knutson KL, Achenbach SJ, Strausbauch MA, Therneau TM, Matteson EL, Gabriel SE, Wettstein PJ.

Clin Immunol. 2020 Jan 8;211:108342. doi: 10.1016/j.clim.2020.108342. [Epub ahead of print]

PMID:
31926330
4.

Comparison of Biologic Discontinuation in Patients With Elderly-Onset Versus Younger-Onset Rheumatoid Arthritis.

Richter MD, Matteson EL, Davis JM 3rd, Achenbach SJ, Crowson CS.

ACR Open Rheumatol. 2019 Oct 26;1(10):627-631. doi: 10.1002/acr2.11083. eCollection 2019 Dec.

5.

Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity.

Coffey CM, Crowson CS, Myasoedova E, Matteson EL, Davis JM 3rd.

Mayo Clin Proc. 2019 Nov;94(11):2241-2248. doi: 10.1016/j.mayocp.2019.05.023. Epub 2019 Oct 13.

PMID:
31619364
6.

Older Drugs With Limited Trial Evidence: Are They Worth the Expense?

Duarte-García A, Matteson EL, Shah ND.

Ann Intern Med. 2019 Oct 15;171(8):602. doi: 10.7326/L19-0520. No abstract available.

PMID:
31610565
7.

Treat to Target: A Valid Concept for Management of Polymyalgia Rheumatica and Giant Cell Arteritis?

Camellino D, Dejaco C, Buttgereit F, Matteson EL.

Rheum Dis Clin North Am. 2019 Nov;45(4):549-567. doi: 10.1016/j.rdc.2019.07.005. Review.

PMID:
31564296
8.

Definition and construct validation of clinically relevant cutoffs on the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire.

Myasoedova E, De Thurah A, Erpelding ML, Schneeberger EE, Maribo T, Citera G, Davis JM, Matteson EL, Crowson CS, Fautrel B, Guillemin F.

Semin Arthritis Rheum. 2019 Sep 11. pii: S0049-0172(19)30330-0. doi: 10.1016/j.semarthrit.2019.09.004. [Epub ahead of print]

PMID:
31526593
9.

Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis.

Ungprasert P, Ryu JH, Matteson EL.

Mayo Clin Proc Innov Qual Outcomes. 2019 Aug 2;3(3):358-375. doi: 10.1016/j.mayocpiqo.2019.04.006. eCollection 2019 Sep. Review.

10.

Mechanisms of lung disease development in rheumatoid arthritis.

Wang D, Zhang J, Lau J, Wang S, Taneja V, Matteson EL, Vassallo R.

Nat Rev Rheumatol. 2019 Oct;15(10):581-596. doi: 10.1038/s41584-019-0275-x. Epub 2019 Aug 27. Review.

PMID:
31455869
11.

Increased hospitalization rates following heart failure diagnosis in rheumatoid arthritis as compared to the general population.

Myasoedova E, Davis JM 3rd, Matteson EL, Achenbach SJ, Setoguchi S, Dunlay SM, Roger VL, Gabriel SE, Crowson CS.

Semin Arthritis Rheum. 2019 Jul 15. pii: S0049-0172(19)30212-4. doi: 10.1016/j.semarthrit.2019.07.006. [Epub ahead of print]

PMID:
31376995
12.

Changes in the Presentation of Incident Gout and the Risk of Subsequent Flares: A Population-based Study over 20 Years.

Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, Bongartz T.

J Rheumatol. 2019 Jul 15. pii: jrheum.190346. doi: 10.3899/jrheum.190346. [Epub ahead of print]

PMID:
31308206
13.

Optimization of flare management in patients with rheumatoid arthritis: results of a randomized controlled trial.

Myasoedova E, Crowson CS, Giblon RE, McCarthy-Fruin K, Schaffer DE, Wright K, Matteson EL, Davis JM 3rd.

Clin Rheumatol. 2019 Nov;38(11):3025-3032. doi: 10.1007/s10067-019-04664-5. Epub 2019 Jul 1.

PMID:
31264032
14.

The Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Berti A, Matteson EL, Crowson CS, Specks U, Cornec D.

J Rheumatol. 2019 Sep;46(9):1243. doi: 10.3899/jrheum.181351. Epub 2019 Jul 1. No abstract available.

PMID:
31263074
15.

Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis.

Hu Y, Wang B, Shen J, Low SA, Putt KS, Niessen HWM, Matteson EL, Murphy L, Ruppert C, Jansen G, Oliver SJ, Feng Y, Dimitrov DS, Nickerson-Nutter C, Low PS.

Arthritis Res Ther. 2019 Jun 7;21(1):143. doi: 10.1186/s13075-019-1912-0.

16.

Pulmonary Complications of Rheumatoid Arthritis.

Farquhar H, Vassallo R, Edwards AL, Matteson EL.

Semin Respir Crit Care Med. 2019 Apr;40(2):194-207. doi: 10.1055/s-0039-1683995. Epub 2019 May 28.

PMID:
31137060
17.

Reply.

Duarte-García A, Crowson CS, Warrington KJ, Matteson EL.

Arthritis Rheumatol. 2019 Oct;71(10):1769-1770. doi: 10.1002/art.41000. Epub 2019 Aug 29. No abstract available.

PMID:
31135097
18.

Older Drugs With Limited Trial Evidence: Are They Worth the Expense? The Case of Repository Corticotropin Marketed as H.P. Acthar Gel.

Duarte-García A, Matteson EL, Shah ND.

Ann Intern Med. 2019 Jun 4;170(11):791-792. doi: 10.7326/M18-3513. Epub 2019 May 28. No abstract available.

PMID:
31060052
19.

Trends in Prevalence of Functional Disability in Rheumatoid Arthritis Compared With the General Population.

Myasoedova E, Davis JM 3rd, Achenbach SJ, Matteson EL, Crowson CS.

Mayo Clin Proc. 2019 Jun;94(6):1035-1039. doi: 10.1016/j.mayocp.2019.01.002. Epub 2019 May 1.

PMID:
31054771
20.

The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study.

Duarte-García A, Pham MM, Crowson CS, Amin S, Moder KG, Pruthi RK, Warrington KJ, Matteson EL.

Arthritis Rheumatol. 2019 Sep;71(9):1545-1552. doi: 10.1002/art.40901. Epub 2019 Aug 1.

PMID:
30957430
21.

2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.

Ehlers L, Askling J, Bijlsma HW, Cid MC, Cutolo M, Dasgupta B, Dejaco C, Dixon WG, Feltelius N, Finckh A, Gilbert K, Mackie SL, Mahr A, Matteson EL, Neill L, Salvarani C, Schmidt WA, Strangfeld A, van Vollenhoven RF, Buttgereit F.

Ann Rheum Dis. 2019 Sep;78(9):1160-1166. doi: 10.1136/annrheumdis-2018-214755. Epub 2019 Mar 21.

PMID:
30898837
22.

The Case for Adaptive Neuromodulation to Treat Severe Intractable Mental Disorders.

Provenza NR, Matteson ER, Allawala AB, Barrios-Anderson A, Sheth SA, Viswanathan A, McIngvale E, Storch EA, Frank MJ, McLaughlin NCR, Cohn JF, Goodman WK, Borton DA.

Front Neurosci. 2019 Feb 26;13:152. doi: 10.3389/fnins.2019.00152. eCollection 2019.

23.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

24.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

25.

Association of Smoking and Obesity on the Risk of Developing Primary Sjögren Syndrome: A Population-based Cohort Study.

Servioli L, Maciel G, Nannini C, Crowson CS, Matteson EL, Cornec D, Berti A.

J Rheumatol. 2019 Jul;46(7):727-730. doi: 10.3899/jrheum.180481. Epub 2019 Jan 15.

PMID:
30647188
26.

Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease.

Zhang J, Wang D, Wang L, Wang S, Roden AC, Zhao H, Li X, Prakash YS, Matteson EL, Tschumperlin DJ, Vassallo R.

Am J Physiol Lung Cell Mol Physiol. 2019 Mar 1;316(3):L487-L497. doi: 10.1152/ajplung.00301.2018. Epub 2019 Jan 3.

PMID:
30604628
27.

Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases.

Mira-Avendano I, Abril A, Burger CD, Dellaripa PF, Fischer A, Gotway MB, Lee AS, Lee JS, Matteson EL, Yi ES, Ryu JH.

Mayo Clin Proc. 2019 Feb;94(2):309-325. doi: 10.1016/j.mayocp.2018.09.002. Epub 2018 Dec 14. Review.

PMID:
30558827
28.

Longitudinal Occurrence and Predictors of Patient-Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis: A Case-Control Study.

Challa DNV, Kvrgic Z, Crowson CS, Matteson EL, Mason TG, Michet CJ Jr, Schaffer DE, Wright KA, Davis JM 3rd.

Arthritis Care Res (Hoboken). 2020 Jan;72(1):18-26. doi: 10.1002/acr.23819. Epub 2019 Dec 10.

PMID:
30506552
29.

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P.

N Engl J Med. 2018 Dec 6;379(23):2209-2219. doi: 10.1056/NEJMoa1801562. Epub 2018 Oct 20.

30.

Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort.

Berti A, Cornec-Le Gall E, Cornec D, Casal Moura M, Matteson EL, Crowson CS, Ravindran A, Sethi S, Fervenza FC, Specks U.

Nephrol Dial Transplant. 2019 Sep 1;34(9):1508-1517. doi: 10.1093/ndt/gfy250.

31.

Prevention of glucocorticoid morbidity in giant cell arteritis.

Buttgereit F, Matteson EL, Dejaco C, Dasgupta B.

Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii11-ii21. doi: 10.1093/rheumatology/kex459. Review.

PMID:
29982779
32.

Large-vessel giant cell arteritis: diagnosis, monitoring and management.

Koster MJ, Matteson EL, Warrington KJ.

Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii32-ii42. doi: 10.1093/rheumatology/kex424. Review.

PMID:
29982778
33.

Hospitalization Increases the Risk of Acute Arthritic Flares in Gout: A Population-based Study over 2 Decades.

Zleik N, Elfishawi MM, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, Bongartz T.

J Rheumatol. 2018 Aug;45(8):1188-1191. doi: 10.3899/jrheum.171320. Epub 2018 Jul 1.

34.

Spontaneous Pneumomediastinum in Connective Tissue Diseases.

De Giacomi F, Baqir M, Cox CW, Moua T, Matteson EL, Ryu JH.

J Clin Rheumatol. 2019 Sep;25(6):239-245. doi: 10.1097/RHU.0000000000000835.

PMID:
29916965
35.

Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease.

Mango RL, Matteson EL, Crowson CS, Ryu JH, Makol A.

Lung. 2018 Aug;196(4):409-416. doi: 10.1007/s00408-018-0126-6. Epub 2018 May 21.

PMID:
29785507
36.

Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study.

Berti A, Matteson EL, Crowson CS, Specks U, Cornec D.

Mayo Clin Proc. 2018 May;93(5):597-606. doi: 10.1016/j.mayocp.2018.02.010. Epub 2018 Mar 24.

37.

Risk of fragility fracture among patients with sarcoidosis: a population-based study 1976-2013-supplementary presentation.

Ungprasert P, Crowson CS, Matteson EL.

Osteoporos Int. 2018 May;29(5):1201. doi: 10.1007/s00198-017-4074-4. Epub 2018 Mar 22.

PMID:
29569153
38.

Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).

van der Heijde D, Daikh DI, Betteridge N, Burmester GR, Hassett AL, Matteson EL, van Vollenhoven R, Lakhanpal S.

Arthritis Rheumatol. 2018 Jun;70(6):826-831. doi: 10.1002/art.40448. Epub 2018 Mar 13.

39.

Hospitalisation rates among patients with primary Sjögren's syndrome: a population-based study, 1995-2016.

Maciel G, Servioli L, Nannini C, Berti A, Crowson CS, Achenbach SJ, Matteson EL, Cornec D.

RMD Open. 2018 Feb 28;4(1):e000575. doi: 10.1136/rmdopen-2017-000575. eCollection 2018.

40.

Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).

van der Heijde D, Daikh DI, Betteridge N, Burmester GR, Hassett AL, Matteson EL, van Vollenhoven R, Lakhanpal S.

Ann Rheum Dis. 2018 Jun;77(6):829-832. doi: 10.1136/annrheumdis-2017-212565. Epub 2018 Mar 13.

PMID:
29525777
41.

Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index.

Berti A, Cornec D, Medina Inojosa JR, Matteson EL, Murad MH.

Semin Arthritis Rheum. 2018 Aug;48(1):77-82. doi: 10.1016/j.semarthrit.2017.12.009. Epub 2018 Jan 6. Review.

PMID:
29496228
42.

Clinical Correlates, Outcomes, and Predictors of Inflammatory Ocular Disease Associated with Rheumatoid Arthritis in the Biologic Era.

Caimmi C, Crowson CS, Smith WM, Matteson EL, Makol A.

J Rheumatol. 2018 May;45(5):595-603. doi: 10.3899/jrheum.170437. Epub 2018 Feb 15.

PMID:
29449499
43.

Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis.

Mandelin AM 2nd, Homan PJ, Shaffer AM, Cuda CM, Dominguez ST, Bacalao E, Carns M, Hinchcliff M, Lee J, Aren K, Thakrar A, Montgomery AB, Bridges SL Jr, Bathon JM, Atkinson JP, Fox DA, Matteson EL, Buckley CD, Pitzalis C, Parks D, Hughes LB, Geraldino-Pardilla L, Ike R, Phillips K, Wright K, Filer A, Kelly S, Ruderman EM, Morgan V, Abdala-Valencia H, Misharin AV, Budinger GS, Bartom ET, Pope RM, Perlman H, Winter DR.

Arthritis Rheumatol. 2018 Jun;70(6):841-854. doi: 10.1002/art.40453. Epub 2018 May 3.

44.

Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease?

Muratore F, Kermani TA, Crowson CS, Koster MJ, Matteson EL, Salvarani C, Warrington KJ.

Arthritis Care Res (Hoboken). 2018 Sep;70(9):1406-1411. doi: 10.1002/acr.23498. Epub 2018 Aug 12.

45.

Orthopedic Surgery Among Patients With Rheumatoid Arthritis: A Population-Based Study to Identify Risk Factors, Sex Differences, and Time Trends.

Richter MD, Crowson CS, Matteson EL, Makol A.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1546-1550. doi: 10.1002/acr.23499. Epub 2018 Sep 7.

46.

The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-based Study over 20 Years.

Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, Bongartz T.

J Rheumatol. 2018 Apr;45(4):574-579. doi: 10.3899/jrheum.170806. Epub 2017 Dec 15.

47.

Increased Risk of Multimorbidity in Patients With Sarcoidosis: A Population-Based Cohort Study 1976 to 2013.

Ungprasert P, Matteson EL, Crowson CS.

Mayo Clin Proc. 2017 Dec;92(12):1791-1799. doi: 10.1016/j.mayocp.2017.09.015. Epub 2017 Nov 3.

48.

Neurosarcoidosis.

Ungprasert P, Matteson EL.

Rheum Dis Clin North Am. 2017 Nov;43(4):593-606. doi: 10.1016/j.rdc.2017.06.008. Epub 2017 Aug 23. Review.

PMID:
29061245
49.

Clinical Characteristics of Ocular Sarcoidosis: A Population-Based Study 1976-2013.

Ungprasert P, Tooley AA, Crowson CS, Matteson EL, Smith WM.

Ocul Immunol Inflamm. 2019;27(3):389-395. doi: 10.1080/09273948.2017.1386791. Epub 2017 Oct 12.

50.

Accuracy of Diagnostic Coding for Sarcoidosis in Electronic Databases: A Population-Based Study.

Ungprasert P, Matteson EL, Crowson CS.

Lung. 2017 Dec;195(6):713-715. doi: 10.1007/s00408-017-0054-x. Epub 2017 Oct 9.

Supplemental Content

Loading ...
Support Center